Ravi Chari

Ravi Chari is a pioneer in antibody drug conjugate chemistry and spent decades developing maytansinoid based ADC platforms. His work at ImmunoGen contributed to the development of trastuzumab emtansine and several subsequent clinical ADCs. He has authored foundational publications on linker design and payload selection for targeted cancer therapy. His contributions shaped modern bioconjugation approaches used across the ADC field.